|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
|
ATE87659T1
(de)
|
1986-09-02 |
1993-04-15 |
Enzon Lab Inc |
Bindungsmolekuele mit einzelpolypeptidkette.
|
|
HUT53672A
(en)
|
1988-02-25 |
1990-11-28 |
Gen Hospital Corp |
Quick immunoselective cloning process
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
US6172197B1
(en)
|
1991-07-10 |
2001-01-09 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
|
KR100206524B1
(ko)
|
1990-07-13 |
1999-07-01 |
어니스트 엠. 해데드 |
씨디 53 세포 표면 항원 및 그를 암호화하는 재조합 디엔에이
|
|
US5932448A
(en)
|
1991-11-29 |
1999-08-03 |
Protein Design Labs., Inc. |
Bispecific antibody heterodimers
|
|
ES2341666T3
(es)
|
1991-12-02 |
2010-06-24 |
Medimmune Limited |
Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
|
|
ATE199392T1
(de)
|
1992-12-04 |
2001-03-15 |
Medical Res Council |
Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
|
|
WO1994017184A1
(en)
|
1993-01-29 |
1994-08-04 |
Schering Corporation |
Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto
|
|
GB9424449D0
(en)
|
1994-12-02 |
1995-01-18 |
Wellcome Found |
Antibodies
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
AUPO591797A0
(en)
|
1997-03-27 |
1997-04-24 |
Commonwealth Scientific And Industrial Research Organisation |
High avidity polyvalent and polyspecific reagents
|
|
WO1998016245A1
(fr)
|
1996-10-15 |
1998-04-23 |
Shionogi & Co., Ltd. |
Procede de determination d'un auto-anticorps
|
|
WO1998016254A1
(en)
|
1996-10-17 |
1998-04-23 |
Immunomedics, Inc. |
Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system
|
|
WO2000006194A2
(en)
|
1997-02-05 |
2000-02-10 |
Biotransplant, Inc. |
Depletion of cells responsible for antibody-mediated graft rejection
|
|
ES2248898T3
(es)
|
1997-05-02 |
2006-03-16 |
The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services |
Inmunotoxinas que comprenden una proteina onc dirigida contra celulas malignas.
|
|
WO1999062526A2
(en)
|
1998-06-05 |
1999-12-09 |
Mayo Foundation For Medical Education And Research |
Use of genetically engineered antibodies to cd38 to treat multiple myeloma
|
|
US7223397B1
(en)
|
1999-01-07 |
2007-05-29 |
Research Development Foundation |
Potentiation of anti-CD38-Immunotoxin cytotoxicity
|
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US7829693B2
(en)
|
1999-11-24 |
2010-11-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
|
WO2001060803A1
(en)
|
2000-02-15 |
2001-08-23 |
Yamanouchi Pharmaceutical Co., Ltd. |
Fused imidazolium derivatives
|
|
FR2807767B1
(fr)
|
2000-04-12 |
2005-01-14 |
Lab Francais Du Fractionnement |
Anticorps monoclonaux anti-d
|
|
AU2001265418B2
(en)
|
2000-06-22 |
2006-03-30 |
Biogen Idec Inc. |
Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
|
|
EP1174440A1
(en)
|
2000-07-19 |
2002-01-23 |
U-BISys B.V. |
A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
|
|
US6955884B2
(en)
|
2000-10-17 |
2005-10-18 |
Trudeau Institute, Inc. |
Methods for identifying compounds that inhibit CD38 activity
|
|
US20070042436A1
(en)
|
2000-10-17 |
2007-02-22 |
Lund Frances E |
CD38 modulated chemotaxis
|
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
|
US20040166490A1
(en)
|
2002-12-17 |
2004-08-26 |
Morris David W. |
Novel therapeutic targets in cancer
|
|
CA2489004C
(en)
|
2002-06-13 |
2013-01-08 |
Crucell Holland B.V. |
Agonistic binding molecules to the human ox40 receptor
|
|
ES2532399T3
(es)
|
2003-03-05 |
2015-03-26 |
Halozyme, Inc. |
Glicoproteína hialuronidasa soluble (sHASEGP), proceso para prepararla, usos y composiciones farmacéuticas que la comprenden
|
|
CN100343248C
(zh)
|
2003-04-15 |
2007-10-17 |
安斯泰来制药株式会社 |
溴化物及其晶体
|
|
MXPA05012723A
(es)
|
2003-05-30 |
2006-02-08 |
Genentech Inc |
Tratamiento con anticuerpos anti-vgf.
|
|
US8597911B2
(en)
|
2003-06-11 |
2013-12-03 |
Chugai Seiyaku Kabushiki Kaisha |
Process for producing antibodies
|
|
US7902338B2
(en)
|
2003-07-31 |
2011-03-08 |
Immunomedics, Inc. |
Anti-CD19 antibodies
|
|
EP1689435A4
(en)
|
2003-10-22 |
2007-10-03 |
Univ Rochester |
ANTI-THYMOCYTE ANTISERUM AND ITS USE FOR TRIGGERING B-CELL APOPTOSIS
|
|
CA2544951A1
(en)
|
2003-11-04 |
2005-05-19 |
Chiron Corporation |
Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
|
|
WO2005063819A2
(en)
|
2003-12-23 |
2005-07-14 |
Crucell Holland B.V. |
Human binding molecule against cd1a
|
|
US8263746B2
(en)
|
2004-02-06 |
2012-09-11 |
Morphosys Ag |
Anti-CD38 human antibodies and uses thereof
|
|
DK2511297T3
(en)
|
2004-02-06 |
2015-06-15 |
Morphosys Ag |
Human anti-CD38 antibodies and their applications
|
|
EP2567976B1
(en)
|
2005-03-23 |
2017-07-19 |
Genmab A/S |
Antibodies against CD38 for treatment of multiple myeloma
|
|
EP3050963B1
(en)
|
2005-03-31 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
Process for production of polypeptide by regulation of assembly
|
|
RU2494107C2
(ru)
|
2005-05-09 |
2013-09-27 |
Оно Фармасьютикал Ко., Лтд. |
Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
|
|
TW200745162A
(en)
|
2005-05-24 |
2007-12-16 |
Morphosys Ag |
Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
|
|
EP2860192B1
(en)
|
2005-10-12 |
2017-09-27 |
MorphoSys AG |
Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38
|
|
EP1968636A4
(en)
|
2005-12-09 |
2010-06-02 |
Seattle Genetics Inc |
METHOD OF USE OF CD40 BONDING AGENTS
|
|
US8871912B2
(en)
|
2006-03-24 |
2014-10-28 |
Merck Patent Gmbh |
Engineered heterodimeric protein domains
|
|
WO2007147901A1
(en)
|
2006-06-22 |
2007-12-27 |
Novo Nordisk A/S |
Production of bispecific antibodies
|
|
US20080063642A1
(en)
|
2006-08-02 |
2008-03-13 |
Adelman Daniel C |
Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of certain hematologic disorders
|
|
WO2008073160A2
(en)
|
2006-08-17 |
2008-06-19 |
The Trustees Of Columbia University In The City Of New York |
Methods for converting or inducing protective immunity
|
|
EP3569245A1
(en)
|
2006-09-26 |
2019-11-20 |
Genmab A/S |
Combination treatment of cd38-expressing tumors
|
|
EP1914242A1
(en)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
|
US7618992B2
(en)
|
2006-12-29 |
2009-11-17 |
Astellas Pharma Inc. |
Method of treating cancer by co-administration of anticancer agents
|
|
AU2008228823A1
(en)
|
2007-03-22 |
2008-09-25 |
Imclone Llc |
Stable antibody formulations
|
|
WO2008119353A1
(en)
|
2007-03-29 |
2008-10-09 |
Genmab A/S |
Bispecific antibodies and methods for production thereof
|
|
CA2682292A1
(en)
|
2007-03-30 |
2008-10-09 |
Medimmune, Llc |
Aqueous formulation comprising an anti-human interferon alpha antibody
|
|
AU2008260445A1
(en)
|
2007-06-01 |
2008-12-11 |
Biogen Idec Ma Inc. |
Cripto binding molecules
|
|
HRP20131167T1
(hr)
|
2007-06-18 |
2014-01-03 |
Merck Sharp & Dohme B.V. |
Antitijela za humani receptor programirane smrti pd-1
|
|
US20090076249A1
(en)
|
2007-09-19 |
2009-03-19 |
Michel De Weers |
Antibodies against CD38 for treatment of multiple myeloma
|
|
MX2010005099A
(es)
|
2007-11-09 |
2010-05-27 |
Novartis Ag |
Usos de anticuerpos anti-cd40.
|
|
JP2011507519A
(ja)
|
2007-12-19 |
2011-03-10 |
セントコア・オーソ・バイオテツク・インコーポレーテツド |
ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法
|
|
ES2563027T3
(es)
|
2008-01-07 |
2016-03-10 |
Amgen Inc. |
Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
|
|
AU2009221916A1
(en)
|
2008-03-03 |
2009-09-11 |
Dyax Corp. |
Metalloproteinase 9 and metalloproteinase 2 binding proteins
|
|
KR20140130512A
(ko)
|
2008-03-06 |
2014-11-10 |
할로자임, 아이엔씨 |
가용성 히알루로니다아제의 대규모 제조
|
|
TWI489994B
(zh)
|
2008-03-17 |
2015-07-01 |
Baxter Healthcare Sa |
供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
|
|
AU2009228616B2
(en)
|
2008-03-25 |
2014-07-24 |
Roche Glycart Ag |
Use of a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity (ADCC) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-Hodgkin' s lymphomas
|
|
KR20100135291A
(ko)
|
2008-04-14 |
2010-12-24 |
할로자임, 아이엔씨 |
히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도
|
|
TWI394580B
(zh)
|
2008-04-28 |
2013-05-01 |
Halozyme Inc |
超快起作用胰島素組成物
|
|
BRPI0910482A2
(pt)
|
2008-04-29 |
2019-09-24 |
Abbott Lab |
imunoglobinas de domínio variável duplo e usos das mesmas
|
|
PT2342227E
(pt)
|
2008-11-07 |
2015-11-13 |
Amgen Res Munich Gmbh |
Tratamento da leucemia linfoblástica aguda
|
|
EP2191842A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
|
|
EP2191841A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
|
|
EP2191840A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
|
|
EP2191843A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
|
|
JP2012525149A
(ja)
|
2009-04-27 |
2012-10-22 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
ヘテロ多量体分子を作製するための方法
|
|
SMT202000092T1
(it)
|
2009-05-14 |
2020-05-08 |
Ambit Biosciences Corp |
Formulazione essiccata a spruzzo o liofilizzata di ac220
|
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
|
MX2012003282A
(es)
|
2009-09-17 |
2012-04-30 |
Baxter Healthcare Sa |
Co-formulacion estable de hialuronidasa e inmunoglobulina, y metodos de su uso.
|
|
WO2011044368A1
(en)
|
2009-10-07 |
2011-04-14 |
Macrogenics, Inc. |
Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
|
|
EP2327725A1
(en)
|
2009-11-26 |
2011-06-01 |
InflaRx GmbH |
Anti-C5a binding moieties with high blocking activity
|
|
US9956165B2
(en)
|
2010-03-01 |
2018-05-01 |
Cytodyn Inc. |
Concentrated protein formulations and uses thereof
|
|
GB201003701D0
(en)
|
2010-03-05 |
2010-04-21 |
Cilian Ag |
System for the expression of a protein
|
|
US20130137134A1
(en)
|
2010-03-29 |
2013-05-30 |
Ben Gurion University Of The Negev Research And Development Authority |
Method and system for detecting and monitoring hematological cancer
|
|
DK2560993T3
(da)
|
2010-04-20 |
2024-10-14 |
Genmab As |
Heterodimeric antibody fc-containing proteins and methods for production thereof
|
|
US9527926B2
(en)
|
2010-05-14 |
2016-12-27 |
Rinat Neuroscience Corp. |
Heterodimeric proteins and methods for producing and purifying them
|
|
DK2580243T3
(da)
|
2010-06-09 |
2020-01-13 |
Genmab As |
Antibodies against human cd38
|
|
EP2420253A1
(en)
|
2010-08-20 |
2012-02-22 |
Leadartis, S.L. |
Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
|
|
SI2621531T1
(sl)
|
2010-09-27 |
2017-06-30 |
Morphosys Ag |
Anti-cd38 protitelo in lenalidomid ali bortezomib za zdravljenje multiplega mieloma in nhl
|
|
PL2635607T3
(pl)
|
2010-11-05 |
2020-05-18 |
Zymeworks Inc. |
Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
|
|
US9358233B2
(en)
|
2010-11-29 |
2016-06-07 |
Boehringer Ingelheim International Gmbh |
Method for treating acute myeloid leukemia
|
|
UA112170C2
(uk)
|
2010-12-10 |
2016-08-10 |
Санофі |
Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
|
|
CL2013001944A1
(es)
|
2010-12-30 |
2014-09-12 |
Takeda Pharmaceutical |
Anticuerpo aislado que se une especificamente a cd38 humana y cd38 de cinomolgo; acido nucleico que lo codifica; celula huesped; metodo de produccion; y su uso para tratar una enfermedad autoinmune.
|
|
JOP20210044A1
(ar)
*
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
|
CN103703000B
(zh)
|
2011-03-23 |
2015-11-25 |
安姆根有限公司 |
Cdk4/6和flt3的稠合三环双重抑制剂
|
|
US20140051662A1
(en)
|
2011-04-08 |
2014-02-20 |
Ab Science |
Treatment of multiple myeloma with masitinib
|
|
US9993529B2
(en)
|
2011-06-17 |
2018-06-12 |
Halozyme, Inc. |
Stable formulations of a hyaluronan-degrading enzyme
|
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
|
US20140309183A1
(en)
|
2011-08-24 |
2014-10-16 |
David Kerr |
Low-Dose Combination Chemotherapy
|
|
EP2561868A1
(en)
|
2011-08-24 |
2013-02-27 |
Anton Bernhard Van Oosten |
Pharmaceutical compositions comprising hydroxychloroquine (HCQ), Curcumin, Piperine/BioPerine and uses thereof in the medical field
|
|
SG10201603411WA
(en)
|
2011-10-28 |
2016-07-28 |
Teva Pharmaceuticals Australia Pty Ltd |
Polypeptide constructs and uses thereof
|
|
WO2013083140A1
(en)
|
2011-12-07 |
2013-06-13 |
N.V. Nutricia |
Beta-lactoglobulin peptides for treating cow's milk protein allergy
|
|
EP3130347B1
(en)
|
2011-12-30 |
2019-09-18 |
Halozyme, Inc. |
Ph20 polypeptide variants, formulations and uses thereof
|
|
WO2013164837A1
(en)
|
2012-03-07 |
2013-11-07 |
Cadila Healthcare Limited |
Pharmaceutical formulations of tnf-alpha antibodies
|
|
HRP20181187T1
(hr)
|
2012-04-04 |
2018-09-21 |
Halozyme, Inc. |
Kombinirana terapija s hijaluronidazom i taksanom koji ciljano djeluje na tumor
|
|
EA033110B1
(ru)
|
2012-04-11 |
2019-08-30 |
Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез |
Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы
|
|
CN113967253A
(zh)
|
2012-05-15 |
2022-01-25 |
百时美施贵宝公司 |
通过破坏pd-1/pd-l1信号传输的免疫治疗
|
|
US9682143B2
(en)
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
JP6426093B2
(ja)
|
2012-09-25 |
2018-11-28 |
モルフォシス・アーゲー |
組み合わせ及びその使用
|
|
ES2621377T3
(es)
|
2012-11-05 |
2017-07-03 |
Morphosys Ag |
Anticuerpo marcado radiactivamente y usos del mismo
|
|
UA118255C2
(uk)
|
2012-12-07 |
2018-12-26 |
Санофі |
Композиція, яка містить антитіло до cd38 і леналідомід
|
|
AU2013364043B2
(en)
|
2012-12-21 |
2018-01-04 |
Seagen Inc. |
Anti-NTB-A antibodies and related compositions and methods
|
|
WO2014142220A1
(ja)
|
2013-03-13 |
2014-09-18 |
アステラス製薬株式会社 |
抗腫瘍剤
|
|
US20140271644A1
(en)
|
2013-03-15 |
2014-09-18 |
Memorial Sloan-Kettering Cancer Center |
Combination/adjuvant therapy for wt-1-positive disease
|
|
ES2774976T3
(es)
|
2013-04-29 |
2020-07-23 |
Teva Pharmaceuticals Australia Pty Ltd |
Anticuerpos anti-CD38 y fusiones con interferón alfa-2b atenuado
|
|
US20140356318A1
(en)
|
2013-05-28 |
2014-12-04 |
Israel Barken |
Adoptive cell therapy with specific regulatory lymphocytes
|
|
CA2919513A1
(en)
|
2013-07-15 |
2015-01-22 |
Matthew J. Goldstein |
Medical uses of cd38 agonists
|
|
SG10201803288RA
(en)
|
2013-10-31 |
2018-05-30 |
Sanofi Sa |
Specific anti-cd38 antibodies for treating human cancers
|
|
WO2015067570A2
(en)
|
2013-11-06 |
2015-05-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical combinations comprising cd33 antibodies and de-methylating agents
|
|
ES3063961T3
(en)
|
2014-02-14 |
2026-04-21 |
Cellectis |
Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
|
|
US9603927B2
(en)
|
2014-02-28 |
2017-03-28 |
Janssen Biotech, Inc. |
Combination therapies with anti-CD38 antibodies
|
|
US9732154B2
(en)
|
2014-02-28 |
2017-08-15 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
|
|
EP3154581B1
(en)
|
2014-06-16 |
2019-02-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Blocking cd38 using anti-cd38 f(ab')2 to protect nk cells
|
|
WO2015195555A1
(en)
*
|
2014-06-16 |
2015-12-23 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells
|
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
|
MX2017001079A
(es)
|
2014-07-24 |
2017-09-12 |
Bluebird Bio Inc |
Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
|
|
MX386886B
(es)
|
2014-09-09 |
2025-03-12 |
Janssen Biotech Inc |
Combinación de anticuerpos anti-cd38 y ácido todo-trans retinoico para usarse en terapias.
|
|
AU2015358615B2
(en)
|
2014-12-04 |
2021-08-05 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of acute myeloid leukemia
|
|
SI3227339T1
(sl)
|
2014-12-05 |
2022-02-28 |
Memorial Sloan-Kettering Cancer Center |
Himerni antigenski receptorji, ki ciljajo na receptor, povezan z G-proteinom, in njihova uporaba
|
|
EA036379B1
(ru)
|
2014-12-12 |
2020-11-02 |
Блубёрд Био, Инк. |
Химерные антигенные рецепторы к bcma
|
|
MA41555A
(fr)
|
2015-02-17 |
2017-12-26 |
Millennium Pharm Inc |
Polythérapie pour le traitement du cancer
|
|
MX389805B
(es)
|
2015-05-20 |
2025-03-11 |
Janssen Biotech Inc |
Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38.
|
|
HK1251474A1
(zh)
|
2015-06-08 |
2019-02-01 |
豪夫迈‧罗氏有限公司 |
使用抗ox40抗体和pd-1轴结合拮抗剂治疗癌症的方法
|
|
AU2016282674B2
(en)
|
2015-06-22 |
2022-01-13 |
Janssen Biotech, Inc. |
Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
|
|
US20170044265A1
(en)
|
2015-06-24 |
2017-02-16 |
Janssen Biotech, Inc. |
Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
|
|
HRP20240338T1
(hr)
|
2015-06-24 |
2024-05-24 |
Janssen Biotech, Inc. |
Imunomodulacija i liječenje solidnih tumora s protutijelima koja se specifično vežu na cd38
|
|
US20180256551A1
(en)
|
2015-06-29 |
2018-09-13 |
Abraxis Bioscience, Llc |
Methods of treating hematological malignancy using nanoparticle mtor inhibitor combination therapy
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
US10072088B2
(en)
|
2015-08-17 |
2018-09-11 |
Janssen Pharmaceutica, Nv |
Anti-BCMA antibodies and uses thereof
|
|
US10781261B2
(en)
|
2015-11-03 |
2020-09-22 |
Janssen Biotech, Inc. |
Subcutaneous formulations of anti-CD38 antibodies and their uses
|
|
DK3827845T3
(da)
|
2015-11-03 |
2022-05-23 |
Janssen Biotech Inc |
Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf
|
|
US20170121417A1
(en)
|
2015-11-03 |
2017-05-04 |
Janssen Biotech, Inc. |
Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses
|
|
JP2019527678A
(ja)
|
2016-06-28 |
2019-10-03 |
ユーエムセー・ユトレヒト・ホールディング・ベー・フェー |
ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療
|
|
TWI781108B
(zh)
|
2016-07-20 |
2022-10-21 |
比利時商健生藥品公司 |
抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
|
|
EP4282877A3
(en)
|
2016-08-10 |
2024-02-21 |
Legend Biotech Ireland Limited |
Chimeric antigen receptors targeting bcma and methods of use thereof
|
|
US20180117150A1
(en)
|
2016-11-01 |
2018-05-03 |
Janssen Biotech, Inc. |
Combination Therapies for CD38-Positive Hematological Malignances with ANTI-CD38 Antibodies and Cyclophosphamide
|
|
MX2019013514A
(es)
|
2017-05-12 |
2020-01-20 |
Crispr Therapeutics Ag |
Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia.
|
|
AU2018270112A1
(en)
|
2017-05-18 |
2019-12-12 |
Tesaro, Inc. |
Combination therapies for treating cancer
|
|
JP2021502961A
(ja)
|
2017-10-31 |
2021-02-04 |
ヤンセン バイオテツク，インコーポレーテツド |
高リスク多発性骨髄腫の治療方法
|
|
BR112020019710A2
(pt)
|
2018-03-28 |
2021-01-26 |
Takeda Pharmaceutical Company Limited |
métodos para tratar uma doença em um sujeito e para tratar um câncer hematológico em um sujeito, e, forma farmacêutica unitária.
|
|
US20190298827A1
(en)
|
2018-04-03 |
2019-10-03 |
Janssen Biotech, Inc. |
Methods of Treating Multiple Myeloma
|
|
US12012461B2
(en)
|
2018-05-16 |
2024-06-18 |
Janssen Biotech, Inc. |
Methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics
|
|
MA53122A
(fr)
|
2018-07-13 |
2021-05-19 |
Genmab As |
Variants d'anticorps cd38 et leurs utilisations
|
|
WO2020081881A2
(en)
|
2018-10-17 |
2020-04-23 |
Janssen Biotech, Inc. |
Method of providing subcutaneous administration of anti-cd38 antibodies
|
|
EA202191352A1
(ru)
|
2018-11-13 |
2021-08-11 |
Янссен Байотек, Инк. |
Контроль содержания микроэлементов-металлов во время продукции антител к cd38
|
|
JP7303314B2
(ja)
|
2019-01-18 |
2023-07-04 |
ヤンセン バイオテツク，インコーポレーテツド |
Ｇｐｒｃ５ｄキメラ抗原受容体及びそれを発現する細胞
|
|
CN113727729A
(zh)
|
2019-02-22 |
2021-11-30 |
詹森生物科技公司 |
用特异性地结合cd38的抗体、来那度胺和地塞米松的组合治疗新诊断的多发性骨髓瘤的方法
|
|
US20200308296A1
(en)
|
2019-03-28 |
2020-10-01 |
Janssen Biotech, Inc. |
Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Pomalidomide and Dexamethasone
|
|
US20200316197A1
(en)
|
2019-03-28 |
2020-10-08 |
Janssen Biotech, Inc. |
Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib and Dexamethasone
|
|
US20200308284A1
(en)
|
2019-03-28 |
2020-10-01 |
Janssen Biotech, Inc. |
Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Lenalidomide and Dexamethasone
|
|
WO2020194245A1
(en)
|
2019-03-28 |
2020-10-01 |
Janssen Biotech, Inc. |
Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses in combination with bortezomib, melphalan and prednisone
|
|
US20200308297A1
(en)
|
2019-03-28 |
2020-10-01 |
Janssen Biotech, Inc. |
Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses
|
|
US20200405854A1
(en)
|
2019-04-19 |
2020-12-31 |
Janssen Biotech, Inc. |
Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses
|
|
US20200397896A1
(en)
|
2019-04-19 |
2020-12-24 |
Janssen Biotech, Inc. |
Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses
|
|
US20200392242A1
(en)
|
2019-04-19 |
2020-12-17 |
Janssen Biotech, Inc. |
Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses
|
|
CN114286681B
(zh)
|
2019-06-04 |
2024-08-16 |
上海科技大学 |
Nad+和/或nad+抑制剂和/或nad+激动剂的用途及其联合制剂
|
|
US20220275101A1
(en)
|
2021-02-09 |
2022-09-01 |
Janssen Biotech, Inc. |
Use of Approved Anti-CD38 Antibody Drug Product to Treat Light Chain Amyloidosis
|
|
US20220275090A1
(en)
|
2021-02-22 |
2022-09-01 |
Janssen Biotech, Inc. |
Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors
|